Department of Ophthalmology, University Hospital, Hradec Králové, Czech Republic.
Eye (Lond). 2011 Sep;25(9):1138-46. doi: 10.1038/eye.2011.122. Epub 2011 Jun 17.
The purpose of this study was to describe the long-term results of AlphaCor implantations, and to evaluate the main complications and risk factors.
Retrospective analysis of preoperative and follow-up data from 15 AlphaCor implantations. Analysis of outcomes, trends, and associations was performed and compared with data from published clinical trials and a literature review.
The survival rate of the device at 1, 2, and 3 years was 87%, 58%, and 42%, respectively. Postoperative visual acuity ranged from hand movement to 0.8. The most significant complications were stromal melt (nine cases), optic deposition (three eyes), and retroprosthetic membrane formation (three eyes). The most common device-unrelated complication was trauma (three patients). All complications were managed without loss of the eye.
AlphaCor provides a treatment option for patients with corneal blindness in which a donor tissue graft would not succeed.
本研究旨在描述 AlphaCor 植入物的长期结果，并评估主要并发症和风险因素。
回顾性分析 15 例 AlphaCor 植入物的术前和随访数据。对结果、趋势和相关性进行分析，并与已发表的临床试验数据和文献复习进行比较。
该装置在 1、2 和 3 年的存活率分别为 87%、58%和 42%。术后视力范围从手动到 0.8。最显著的并发症是基质溶解（9 例）、光学沉积（3 只眼）和后假体膜形成（3 只眼）。最常见的与器械无关的并发症是外伤（3 例）。所有并发症均未导致眼球丧失。
AlphaCor 为角膜盲患者提供了一种治疗选择，对于这些患者来说，供体组织移植物无法成功。
